16/09/2026 Sling therapeutics dosed the first patient in the Phase 3 trial of linsitinib for TED. Sling therapeutics dosed the first patient in the Phase 3 trial of linsitinib for TED. (Ref) First patient was dosed in Sling Therapeutics’ Phase 3, ORBIT/ NCT07753603 trial evaluating linsitinib (an insulin-like growth factor-1 receptor inhibitor) in adult with moderate to severe active thyroid eye disease (TED). The trial is expected to enroll ~ 130 participants, with the propo

06/04/2026 Tenvie Therapeutics announced dosing of first subject in Phase 1 trial of TNV262 Amgen announced topline results from Phase 3 teprotumumab in active TED Tenvie Therapeutics announced dosing of first subject in Phase 1 trial of TNV262 ( Ref ) Tenvie Therapeutics announced the first subject dosed in a Phase 1 clinical study evaluating TNV262 (a fully CNS-penetrant small molecule inhibitor targeting NLRP3) for the treatment of cardiometabolic diseases, including obesi

02/04/2026 Immunovant announced Phase 3 results for batoclimab in thyroid eye disease Immunovant announced Phase 3 results for batoclimab in thyroid eye disease ( Ref ) Immunovant announced topline results from its two Phase 3 (GO) studies that evaluated batoclimab (an FcRn antagonist) for the treatment of adult patients with active, moderate-to-severe thyroid eye disease (TED) The studies failed to meet their primary endpoint of achieving ≥2mm proptosis responder rate at We